To date, however, it is shown that while adiponectin is decreased, and insulin resistance and dyslipidemia are induced, in a mouse model of obesity/type 2 diabetes, physiological doses of adiponectin improve these conditions in this mouse model (15). This evidence concerns the gene ADIPOQ and metabolic syndrome.